Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00542165 |
To collect under daily practice conditions, clinical data on the changes of sexual function when a new formulation of alfuzosin(Xatral XL® )is administered once daily in patients with lower urinary tract symptoms(LUTS) suggestive of prostatic hypertrophy
Condition | Intervention | Phase |
---|---|---|
BPH/LUTS/Sexual Functions |
Drug: Alfuzosin |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL) in Patients With Benign Prostatic Hypertrophy |
Enrollment: | 166 |
Study Start Date: | March 2004 |
Study Completion Date: | December 2004 |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study ID Numbers: | L_8819 |
Study First Received: | October 9, 2007 |
Last Updated: | October 10, 2007 |
ClinicalTrials.gov Identifier: | NCT00542165 |
Health Authority: | South Korea: Korea Food and Drug Administration (KFDA) |
Pathological Conditions, Anatomical Hyperplasia Hypertrophy Alfuzosin |
Prostatic Diseases Prostatic Hyperplasia Genital Diseases, Male |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Therapeutic Uses Physiological Effects of Drugs |
Adrenergic Antagonists Cardiovascular Agents Adrenergic alpha-Antagonists Antihypertensive Agents Pharmacologic Actions |